title: [Impact of Helicobacter pylori eradication on morphological changes in gastric mucosa].
abstract: The purpose of the study was to examine gastric mucosal morphological changes in patients with gastroduodenal pathology after eradication therapy for Helicobacter pylori (H. pylori). A hundred and thirty-eight patients (40 females and 98 males) were examined. Of them, there were 122 patients with duodenal peptic ulcer, 8 with gastric peptic ulcer, 5 with erosive gastritis, 2 with chronic atrophic antral gastritis, and 1 with non-atrophic gastritis. Two months and a year after therapy, manifestations of gastric mucosal atrophy, the degree of inflammation, and its activity significantly diminished in patients with complete H. pylori eradication. Positive changes were observed mainly in the antral portion of the stomach. In patients with partial eradication, chronic inflammation and its activity became less. Two months and a year following therapy, positive changes in the gastric mucosa were absent in patients without H. pylori eradication.
authors.affiliation: Vitebsk State Medical University, 210009, Vitebsk, Belarus
authors.forename: S I
authors.identifier: 0000-0001-6067-3600
authors.initials: SI
authors.lastname: Pimanov
authors.affiliation: Vitebsk State Medical University, 210009, Vitebsk, Belarus
authors.forename: E V
authors.initials: EV
authors.lastname: Makarenko
authors.affiliation: Vitebsk Regional Bureau of Pathology, 210037, Vitebsk, Belarus
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Krylov
authors.affiliation: Vitebsk State Medical University, 210009, Vitebsk, Belarus
authors.forename: M E
authors.initials: ME
authors.lastname: Matveenko
authors.affiliation: Vitebsk Regional Bureau of Pathology, 210037, Vitebsk, Belarus
authors.forename: S V
authors.initials: SV
authors.lastname: Malashenko
authors.affiliation: Vitebsk State Medical University, 210009, Vitebsk, Belarus
authors.forename: V M
authors.initials: VM
authors.lastname: Bondarenko
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000382:microbiology / Q000473:pathology*; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D005757:Gastritis, Atrophic / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors; D013276:Stomach Ulcer / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors